Literature DB >> 22312065

Complications of radiofrequency ablation of varicose veins.

M A Anwar1, T R A Lane, A H Davies, I J Franklin.   

Abstract

Radiofrequency ablation (RFA) has become a valued weapon in the phlebologist's armoury. It offers ease of use and reproducibility with good outcomes. However, as with all interventions, complications arise. In this review we examine the complications inherent with RFA and their relative risk, with their avoidance measures if available. Overall, we find that RFA offers a very safe procedure with rare severe complications.

Mesh:

Year:  2012        PMID: 22312065     DOI: 10.1258/phleb.2012.012s21

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  5 in total

1.  [Endovenous ablation of saphenous vein varicosis].

Authors:  Sanja Schuller-Petrovic
Journal:  Wien Med Wochenschr       Date:  2016-06-13

2.  Role of PTFE Patch Saphenoplasty in Reducing Neovascularization and Recurrence in Varicose Veins.

Authors:  M G Vashist; Nitin Singhal; Manish Verma; Jyotsana Sen
Journal:  Indian J Surg       Date:  2014-08-28       Impact factor: 0.656

Review 3.  Is radiofrequency ablation of varicose veins a valuable option? A systematic review of the literature with a cost analysis.

Authors:  Thomas G Poder; Jean-François Fisette; Suzanne K Bédard; Marc-Antoine Despatis
Journal:  Can J Surg       Date:  2018-04       Impact factor: 2.089

4.  CASS (CyanoAcrylate closure versus Surgical Stripping for incompetent saphenous veins) study: a randomized controlled trial comparing clinical outcomes after cyanoacrylate closure and surgical stripping for the treatment of incompetent saphenous veins.

Authors:  Sungsin Cho; Hyung Sub Park; Taeseung Lee; Seung Jae Byun; Woo-Sung Yun; Shin-Seok Yang; Hyangkyoung Kim; Woo-Shik Kim; Jin Hyun Joh; In Mok Jung
Journal:  Trials       Date:  2020-06-03       Impact factor: 2.279

5.  Mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins: study protocol for a randomised controlled trial.

Authors:  Amjad Belramman; Roshan Bootun; Tjun Yip Tang; Tristan R A Lane; Alun H Davies
Journal:  Trials       Date:  2018-08-07       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.